• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[接受FEC和AC化疗的乳腺癌患者恶心/呕吐的预测因素]

[Predictive factors of nausea/vomiting of breast cancer patients receiving FEC and AC chemotherapy].

作者信息

Nomura Hisanaga, Kawakami Hideyasu, Nagai Shigeru, Shinohara Takao, Imoto Shigeru, Isaka Hirotsugu

机构信息

Dept. of Pharmacy, Kyorin University Hospital.

出版信息

Gan To Kagaku Ryoho. 2008 Jun;35(6):941-6.

PMID:18633221
Abstract

INTRODUCTION

It is largely believed that nausea/vomiting during cancer chemotherapy is caused by both the medical and personal factors of the patient. This study was aimed at examining whether the monitoring of risk factors prior to the therapy would help predict nausea/vomiting.

METHOD

In the fifteen months between April 2006 and June 2007, breast cancer patients, receiving FEC and AC chemotherapy at the Outpatient Chemotherapy Room, were interviewed. Before they received their first treatment, each patient was asked to reply as to five risk factors: age, history of motion sickness, habitual drinking, history of morning sickness, and anxiety. Three weeks later, when they came back for their second treatment, CTCAE was conducted to assess their symptoms of nausea and vomiting. Fisher's exact probability test was used for the statistical analysis.

RESULTS

49 patients were studied. The relative risk ratios of vomiting were as follows: Age 1.57; motion sickness 2.15; habitual drinking 0.97; morning sickness 1.54; and anxiety 3.15. Only anxiety showed a significant difference(p=0.019). The associated risk ratios of nausea were: age 2.00; motion sickness 1.57; habitual drinking 1.04; morning sickness 1.37; and high levels of anxiety 2.28. Only anxiety showed a significant difference(p=0.018). The number of risk factors did not show a significant difference.

CONCLUSION

The study shows that anxiety may be one of the risk factors that would cause severe nausea or vomiting during cancer chemotherapy.

摘要

引言

人们普遍认为,癌症化疗期间的恶心/呕吐是由患者的医学因素和个人因素共同引起的。本研究旨在探讨在治疗前对危险因素进行监测是否有助于预测恶心/呕吐。

方法

在2006年4月至2007年6月的15个月间,对在门诊化疗室接受FEC和AC化疗的乳腺癌患者进行了访谈。在他们接受首次治疗前,每位患者被要求回答五个危险因素:年龄、晕动病史、习惯性饮酒、晨吐史和焦虑情况。三周后,当他们回来接受第二次治疗时,采用癌症治疗不良反应通用术语标准(CTCAE)来评估他们的恶心和呕吐症状。采用Fisher精确概率检验进行统计分析。

结果

共研究了49例患者。呕吐的相对风险比分别如下:年龄1.57;晕动病2.15;习惯性饮酒0.97;晨吐1.54;焦虑3.15。只有焦虑显示出显著差异(p=0.019)。恶心的相关风险比分别为:年龄2.00;晕动病1.57;习惯性饮酒1.04;晨吐1.37;高度焦虑2.28。只有焦虑显示出显著差异(p=0.018)。危险因素的数量未显示出显著差异。

结论

该研究表明,焦虑可能是导致癌症化疗期间严重恶心或呕吐的危险因素之一。

相似文献

1
[Predictive factors of nausea/vomiting of breast cancer patients receiving FEC and AC chemotherapy].[接受FEC和AC化疗的乳腺癌患者恶心/呕吐的预测因素]
Gan To Kagaku Ryoho. 2008 Jun;35(6):941-6.
2
Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.接受辅助多柔比星和环磷酰胺治疗的乳腺癌患者化疗引起恶心和呕吐的临床预测因素。
Ann Pharmacother. 2009 Mar;43(3):444-52. doi: 10.1345/aph.1L437. Epub 2009 Feb 3.
3
Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity.化疗引起的恶心、呕吐和疲劳——与感觉知觉和自主反应性相关的个体差异的作用。
Psychother Psychosom. 2007;76(6):376-84. doi: 10.1159/000107566.
4
[Provision of information by pharmacists regarding the effective timing of co-administration of first-generation serotonin receptor antagonists and dexamethasone for chemotherapy-induced nausea and vomiting in patients receiving Doxorubicin and cyclophosphamide chemotherapy for breast cancer].[药剂师提供关于第一代5-羟色胺受体拮抗剂与地塞米松联合给药对接受多柔比星和环磷酰胺化疗的乳腺癌患者化疗引起的恶心和呕吐的有效时机的信息]
Gan To Kagaku Ryoho. 2012 Jan;39(1):75-9.
5
Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma.患者期望是化疗后严重恶心的有力预测指标:罗切斯特大学社区临床肿瘤项目对乳腺癌患者的研究。
Cancer. 2004 Dec 1;101(11):2701-8. doi: 10.1002/cncr.20718.
6
[Assessment of nausea and vomiting during FEC regimen for breast cancer after the novel antiemetic agent - introduction using MASCC antiemesis tool].[使用MASCC止吐工具对新型止吐药物引入后乳腺癌FEC方案期间恶心和呕吐的评估]
Gan To Kagaku Ryoho. 2012 Feb;39(2):241-4.
7
[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].盐酸雷莫司琼在乳腺癌CMF或CEF方案化疗中对恶心呕吐的防治作用
Gan To Kagaku Ryoho. 1999 Jul;26(8):1163-70.
8
[The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].[FEC(75)作为日本乳腺癌患者辅助化疗的可行性]
Gan To Kagaku Ryoho. 2005 Nov;32(12):1919-23.
9
Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study.乳腺癌患者化疗引起的恶心和呕吐:一项前瞻性观察研究。
J Support Oncol. 2007 Sep;5(8):374-80.
10
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.阿瑞匹坦、昂丹司琼和地塞米松用于接受中度致吐性化疗的中国乳腺癌患者化疗引起的恶心和呕吐的随机研究。
Breast Cancer Res Treat. 2009 Feb;113(3):529-35. doi: 10.1007/s10549-008-9957-9. Epub 2008 Mar 10.

引用本文的文献

1
Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it.阿瑞匹坦对真正有需求的日本胸段恶性肿瘤患者的治疗性和预防性止吐作用。
Support Care Cancer. 2015 Apr;23(4):905-12. doi: 10.1007/s00520-014-2430-x. Epub 2014 Sep 17.